AlphaCrest Capital Management’s bluebird bio BLUE Stock Holding History

AlphaCrest Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,407	Closed	-$1.08M	–	1253
2021 Q4	$1.08M	Buy	5,407 +3,987	+281%	+$941K	0.04%	752
2021 Q3	$352K	Buy	+1,420	New	+$406K	0.02%	1043
2021 Q2	–	Sell	-1,325	Closed	-$517K	–	1228
2021 Q1	$517K	Buy	1,325 +868	+190%	+$427K	0.03%	779
2020 Q4	$256K	Sell	457 -298	-39%	-$189K	0.02%	978
2020 Q3	$528K	Buy	755 +469	+164%	+$366K	0.06%	555
2020 Q2	$226K	Sell	286 -64	-18%	-$48.3K	0.04%	775
2020 Q1	$209K	Buy	+350	New	+$341K	0.03%	923

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

AlphaCrest Capital Management's BLUE Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of bluebird bio (BLUE) in Q1 2022, closing a stake of 5,407 shares — an estimated $1.08M sold.

AlphaCrest Capital Management first reported a position in BLUE in Q1 2020 and held it in 7 quarters. The position peaked at $1.08M in Q4 2021. 174 funds tracked by Wall St. Rank hold BLUE as of Q1 2022.

AlphaCrest Capital Management reported no remaining bluebird bio position as of Q1 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 5,407 bluebird bio shares in Q1 2022, an estimated $1.08M.
AlphaCrest Capital Management first reported a position in bluebird bio in Q1 2020 and held it in 7 quarters.
AlphaCrest Capital Management's bluebird bio position peaked at $1.08M in Q4 2021.
174 funds tracked by Wall St. Rank held bluebird bio as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.